Brucellosis
8
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Seroprevalence of Brucella Antibodies in High-Risk Patients With Low Back Pain: A Case-Control Study
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
A Multicentre, Retrospective Study of Clinical Characteristics and Long-term Outcomes of Patients With Brucellosis
Investigation of Fever Suspected as a Zoonosis Using Advanced Diagnostic Technologies
Brucella Serology and History of Brucellosis in Patients With Modic Changes Type 1
Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)